Korean Market
OWNR
GeneOne Life Science
★

GeneOne Life Science's 51st EGM Proposes 80% Capital Reduction and Election of Three Inside Directors

 
OTHR
GeneOne Life Science
★★★

80% capital reduction and director election proposed, raising concerns over shareholder value dilution

 
EXCH
GeneOne Life Science
★★

GeneOne Life Science: Non-compliance with multiple corporate governance core indicators and accumulated losses prevent dividends, negatively impacting shareholder rights.

 
MATR
GeneOne Life Science
★

Delay in Receipt of Proceeds from Self-Held Convertible Bond Sale by 2 Months... Increased Liquidity Pressure

 
MATR
GeneOne Life Science
★

GeneOne Life Science Announces 80% Capital Reduction to Offset Deficits: Shares to Plummet from 90.9M to 18.2M, Short-Term Volatility Expected

 
EXCH
GeneOne Life Science
★

Correction of Resolution to Convene EGM... Agenda Added: Business Diversification via Articles Amendment and Capital Reduction Approval

 
OWNR
GeneOne Life Science
★★

GeneOne Life Science Proposes 80% Reverse Stock Split to Cover Deficit, Amends Articles for Business Diversification – Management Turnaround Efforts Amid Shareholder Concerns

 
OTHR
GeneOne Life Science
★★

GeneOne Life Science Announces 80% Reverse Stock Split (5:1) and Major Expansion of Business Objectives... Aimed at Deficit Coverage but Raises Concerns Over Shareholder Value Dilution

 
MATR
GeneOne Life Science
★

Delay in Receipt of Sale Proceeds for Self-Convertible Bonds to May 29, 2026 (KRW 1.5 Billion)

 
MATR
GeneOne Life Science
★

Capital Reduction Correction: Deficit Coverage and Schedule Postponement

 
MATR
GeneOne Life Science
★

51 Billion Won Convertible Bond Issuance: Payment Date Postponed and Investor Change

 
EXCH
GeneOne Life Science
★

Postponement of EGM and Capital Reduction Proposal

 
OTHR
GeneOne Life Science
★★★

Extraordinary Shareholders' Meeting for 80% Capital Reduction and Huge Operating Loss

 
OWNR
GeneOne Life Science
★★★

Massive 80% Capital Reduction and Postponement of EGM

 
OWNR
GeneOne Life Science
★★★

80% Capital Reduction (5→1 Share Consolidation): Capital from 9.09B to 1.82B KRW and Election of 3 Inside Directors